Anti-tumor efficacy of a potent and selective non-covalent KRAS G12D ...
2022年10月10日 — Nature Medicine - A potent and selective inhibitor of KRASG12D, the most common mutant form of the KRAS oncoprotein, has anti-tumor efficacy in multiple pre-clinical cancer models, opening...
Targeting KRAS in cancer | Nature Medicine
2024年4月18日 — Recent data demonstrate that BI-2865 can inhibit many of the common KRAS mutations seen in cancer, including G12D, G12V, G12C and p.Gly13Asp (G13D), as well as wild-type KRAS, which is...
A shared neoantigen vaccine combined with immune checkpoint ... - Nature
2024年3月27日 — These data demonstrate enhanced antigen presentation and T cell responses to KRAS neoantigens utilizing a KRAS-focused vaccine cassette incorporating repetition of four highly prevalent KRAS...
The KRAS crowd targets its next cancer mutations. https://doi.org/10.1038/d41573-023-00015-x. By Asher Mullard. Clinic-ready inhibitors, degraders and molecular glues are pushing cancer frontiers...
Next batter up! Targeting cancers with KRAS-G12D mutations
2023年8月15日 — Activating mutations in codon 12, especially G12D, have the highest prevalence across a range of carcinomas and adenocarcinomas. With inhibitors to KRAS-G12D now entering clinical trials, understanding the biology of KRAS-G12D cancers, and identifying biomarkers that predict therapeutic response is crucial.
Targeting the KRAS G12D Mutant as Potential Therapy in Cancer
2021年8月2日 — The present Patent Highlight relates to certain cyclic heteroaryl compounds and pharmaceutically acceptable salts that inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein. These compounds have inhibitory activity against KRAS G12D mutation and are antitumor agent, wherein the adenocarcinoma is a cancer of the prostate, small intestine ...
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in ... - Nature
2024年1月9日 — Cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using amphiphile (Amph) modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with...
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS …
2021年12月10日 — Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS G12D inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS G12D mutant xenograft mouse tumor model.
Study Shows Promise of New Anti-KRAS Drug for Pancreatic Cancer
Around 36 percent of pancreatic cancers with a KRAS mutation are KRAS G12D-mutant. The small molecule inhibitor used in this study, MRTX1133 (developed by Mirati Therapeutics) specifically targets KRAS G12D, as the company first reported last month in Nature Medicine .
Anti-tumor efficacy of a potent and selective non-covalent KRAS ...
2022年10月10日 — We show that adagrasib is strictly KRAS-but not KRAS(G12C)-specific, due to its strong and unreplaceable interaction with H95. Unlike adagrasib, sotorasib is less dependent on H95 for its...
- 某些结果已被删除